(P070) Quantitative Analysis of Stereotactic Body Radiation Therapy (SBRT)-Induced Lung Injuries

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Radiographic lung density changes are observed in most patients after stereotactic body radiotherapy (SBRT) for lung cancer. In this study, we assessed the relationship between SBRT dose and our treatment technique. Follow-up CT density changes were used as a surrogate for lung injury from SBRT.

Javad Rahimian, PhD, Luis Mariscal, MD, Michael R. Girvigian, MD, Arturo Alfaro, BSc, Michael J. Miller, MD; Southern California Permanente Medical Group

Purpose: Radiographic lung density changes are observed in most patients after stereotactic body radiotherapy (SBRT) for lung cancer. In this study, we assessed the relationship between SBRT dose and our treatment technique. Follow-up CT density changes were used as a surrogate for lung injury from SBRT.

Methods: Six patients with non–small-cell lung carcinoma (NSCLC) were retrospectively assessed. Patients’ 4D-CT scans were acquired, and the reconstructed phase images were imported into the Phillips Medical Systems Pinnacle treatment planning computer. The internal target volume (ITV) for each patient was contoured using 10 to 14 phase image datasets. The planning target volume (PTV) was generated by adding a 5-mm margin to the ITV in the lateral and anterior-posterior directions and by adding a 7.5-mm cranial-caudal margin. Radiation Therapy Oncology Group (RTOG) protocol 0618 was generally followed for PTV dose coverage. A total dose of 48–54 Gy (52.33 ± 2.66 Gy) in three to five (3.50 ± 0.84) fractions to the isocenter was prescribed. Further, seven to nine coplanar and nonopposing conformal beams (8.50 ± 0.84 beams) were placed. The convolution dose algorithm with heterogeneity correction was used for dose calculations. Treatments were delivered on alternate days under cone beam CT (CBCT) image guidance. A follow-up positron emission tomography (PET)/CT scan was acquired 6–14 months (8.50 ± 3.02 mo) after SBRT treatment completion. The follow-up scan was then fused with the original planning CT. The high radiographic density region was contoured to determine the net SBRT-induced volume of lung tissue injury. The minimum dose causing radiographic injury was then determined.

Results: The average and standard deviation for ITV, PTV, radiographic injury, and total lung volumes were calculated to be 12.74 ± 14.70 cm3, 49.67 ± 45.40 cm3, 16.49 ± 13.57 cm3, and 3,452.00 ± 235.00 cm3, respectively. The average radiographic injury volume-to-PTV ratio was 32.27 ± 21.67% (range: 0%–62%). The threshold dose responsible for radiographic injury was 10.70 ± 0.84 Gy, based on the scan acquired at an average of 8.50 months post-SBRT. There is a linear relationship between the biological effective dose (BED) with the radiographic injury volume.

Conclusions: In this study, increased CT density changes, a surrogate for damage to the normal lung tissue, was associated with higher BED and increasing PTV size, with a threshold dose of 10.70 Gy. Therefore, to reduce SBRT-induced lung injury, at least nine conformal equally weighted beams should be used to distribute dose evenly in normal lung tissue. Further, the noncoplanar and nonopposing conformal beams should be used if possible to minimize the radiographic injury. A study of serial follow-up scans of patients, at regular intervals, is warranted to determine the early and late SBRT-induced lung injuries. 

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Related Content